[Pulmonary fibrosis and endovesical mitomycin C].
The Mitomycin C is a chemotherapeutic agent used in several types of carcinomas. In the superficial vesical carcinoma comes using since more than a quarter century in the form of endovesical instillations. It is a drug relatively safe, although there have been described adverse effects related to its systemic administration as myelosuppression, anaemia, kidney toxicity and less frequently pulmonary fibrosis. In this article we presented the case of a patient who suffers a respiratory illness compatible with interstitial lung disease that develops a respiratory severe insufficiency finishing with the death, after the administration of endovesical mitomycin C, being this adverse effect exceptional for this route of administration.
Janeiro Pais
José M
JM
Servicio de Urología, Hospital Juan Canalejo, La Coruña, España. janeiropais@canalejo.org
Casas Agudo
Vicente Pastor
VP
López Garcia
Daniel
D
González Dacal
Juan
J
Lamas Meilán
Cipriano
C
González Martín
Marcelino
M
D000283:Administration, Intravesical; D000368:Aged; D000903:Antibiotics, Antineoplastic / Q000008:administration & dosage* / Q000009:adverse effects*; D017809:Fatal Outcome; D006801:Humans; D008297:Male; D016685:Mitomycin / Q000008:administration & dosage* / Q000009:adverse effects*; D011658:Pulmonary Fibrosis / Q000139:chemically induced*; D001749:Urinary Bladder Neoplasms / Q000188:drug therapy
D000903:Antibiotics, Antineoplastic; D016685:Mitomycin